Drug Profile
Research programme: synthetic natriuretic peptide - Capricor Therapeutics
Alternative Names: CU-NPLatest Information Update: 23 Feb 2017
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Capricor Therapeutics
- Class Natriuretic peptides
- Mechanism of Action Natriuretic peptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Kidney disorders
Most Recent Events
- 16 Feb 2017 Capricor Therapeutics has elected to terminate its license agreement with the Mayo Clinic for natriuretic peptide receptor agonists, including Cenderitide
- 01 Feb 2017 Discontinued - Preclinical for Cardiovascular disorders in USA (Parenteral)
- 01 Feb 2017 Discontinued - Preclinical for Kidney disorders in USA (Parenteral)